Huons Meditech announced on the 4th that it signed a Memorandum of Understanding (MOU) to strengthen business cooperation with LVIS, a digital-based brain disease diagnosis company, at the Huons Group headquarters in Pangyo, Seongnam-si, Gyeonggi-do on the 29th of last month.
Huons Meditech has signed a Memorandum of Understanding (MOU) for joint development and production of medical devices with LVIS. (From left) Cheon Cheong-woon, CEO of Huons Meditech; Yoon Sung-tae, Chairman of Huons Group; Lee Jin-hyung, CEO of LVIS. [Photo by Huons Meditech]
NeuroMatch, developed by LVIS, is an artificial intelligence (AI)-based deep learning platform that analyzes brain neural circuits to diagnose brain diseases such as dementia and epilepsy and suggests optimal treatment methods.
This MOU is an agreement for the joint development and production of medical devices for brain neural analysis to be applied to NeuroMatch through the synergy of the capabilities and technologies of both companies. Huons Meditech plans to focus on the commercialization of NeuroMatch in the future through its medical device development and production capabilities required for the NeuroMatch platform.
A representative of Huons Meditech stated, "We consider this signing very meaningful and will provide wholehearted support and cooperation, concentrating all our capabilities until the commercialization of LVIS’s NeuroMatch."
LVIS is a brain disease diagnosis and treatment company located in Silicon Valley, USA, founded in 2013 by CEO Jin-Hyung Lee, the first Korean woman appointed as a professor at Stanford University. The company holds over 20 patents and possesses more than 140,000 medical data accumulated over 13 years. Huons Meditech is a specialized company producing medical devices, infection control devices, and medical disinfectants, supplying various pharmaceuticals and quasi-drugs based on its medical devices.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
